New trial
Phase II Trial of Reduced-Dose Radiotherapy in HPV+ Oropharyngeal Cancer
- Trial ID
- NCT06902623 on ClinicalTrials.gov
- Cancer type
- Oropharyngeal Cancer
- Location
- 2 Locations
- Published in
- New in Oncology - June 16, 2025
This trial led by Georgetown University evaluates if omitting chemotherapy from full-dose radiotherapy (66Gy) maintains cancer control while reducing long-term side effects in Stage I–II HPV/p16+ oropharyngeal cancer, enrolling patients at sites in Washington and Clinton.
More in head and neck cancer
-
Trial result · Oct 15, 2026 · NCT05323656
Setanaxib + pembrolizumab misses its tumor-shrinkage endpoint but shows exploratory survival signals in CAF-rich head and neck cancer -
Trial result · Oct 1, 2026 · NCT04260126
PDS0101 (HPV16-targeted immunotherapy) + pembrolizumab drives 34% ORR and 39.3-mo mOS in 1L HPV16+ R/M HNSCC -
New trial · Sep 24, 2026 · NCT07773987
Phase 2 pembrolizumab PD-1 inhibitor plus hypofractionated RT tests ENI nodal-sparing strategy -
New trial · Sep 24, 2026 · NCT07807163
Phase 2 ficerafusp alfa (BCA101) EGFR×TGF-β bifunctional antibody + pembrolizumab -
New trial · Sep 24, 2026 · NCT07796126
Phase 2 toripalimab PD-1 (CD279) antibody “priming” before paclitaxel microtubule inhibitor in HNSCC